Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3065 participants.

Also called NCT03037931

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,065 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03037931
Other papers using this trial's data
  • Ferric Carboxymaltose in Heart Failure with Iron Deficiency The New England journal of medicine, 2023-09-14 DOI, PubMed 37632463
  • Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID JACC. Heart failure, 2025-12 DOI, PubMed 41137844

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Bulgaria, Canada, Czechia, Georgia, Hungary, Latvia, Lithuania, New Zealand, Poland, Russia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03037931. Randomized; double masking; primary purpose treatment. Start 2017-03-15 (actual); primary completion 2023-02-02 (actual). Results posted on 2024-07-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
Acronym
HEART-FID
Condition
Heart Failure
Condition
Iron-deficiency
Intervention (Drug)
Ferric Carboxymaltose
Intervention (Drug)
Placebo
Lead sponsor
American Regent, Inc. (class: industry)
Collaborator
Duke Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct03037931
Content hash
e92a9ca90af31f0550c2032d38f0d2424ce7b8b7411b775330a31feec4d379ef